Celularity Inc — Form 8-K
Filed October 29, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Celularity Inc. entered an exclusive manufacturing agreement with Vesalius Longevity Labs to perform downstream purification, processing, analytical testing and manufacturing of Vesalius's Peptual-branded peptide active pharmaceutical ingredients (APIs) at Celularity's Florham Park, New Jersey facility. The collaboration positions the parties to supply peptide APIs to U.S. compounding pharmacies if FDA adds covered peptide substances to its approved bulk drug list. No specific dollar amounts, revenue targets, or timelines were disclosed in the filing.
Why this rating
Early-stage partnership with undefined economics. No revenue committed, no timeline given, regulatory pathway uncertain. Modest use of existing capacity.
See more from October 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.